

Title (en)

THERAPEUTIC COMPOSITION FOR ERECTILE DYSFUNCTION TREATMENT

Title (de)

THERAPEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON EREKTILER DYSFUNKTION

Title (fr)

COMPOSITION THÉRAPEUTIQUE POUR LE TRAITEMENT DE LA DYSFONCTION ÉRECTILE

Publication

**EP 4304598 A1 20240117 (EN)**

Application

**EP 21894156 A 20211118**

Priority

- GE AU2020015494 U 20201119
- IB 2021060706 W 20211118

Abstract (en)

[origin: WO2022107042A1] Composition contains sydenafil citrate and tadalafil as active ingredients, and dicalcium phosphate dihydrate, microcrystalline cellulose, starch sodium glycidolate, colloidal silicon dioxide and magnesium stearate – as pharmaceutically acceptable additives.

IPC 8 full level

**A61K 31/4985** (2006.01); **A61K 9/48** (2006.01); **A61K 31/519** (2006.01); **A61P 15/00** (2006.01)

CPC (source: EP)

**A61K 9/2009** (2013.01); **A61K 9/2013** (2013.01); **A61K 9/2054** (2013.01); **A61K 9/2059** (2013.01); **A61K 31/4985** (2013.01); **A61K 31/519** (2013.01); **A61K 31/57** (2013.01); **A61P 15/00** (2017.12); **A61P 15/10** (2017.12)

C-Set (source: EP)

1. **A61K 31/57 + A61K 2300/00**
2. **A61K 31/4985 + A61K 2300/00**

Citation (search report)

See references of WO 2022107042A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

**WO 2022107042 A1 20220527**; EP 4304598 A1 20240117; GE U20212096 Y 20210927

DOCDB simple family (application)

**IB 2021060706 W 20211118**; EP 21894156 A 20211118; GE AU2020015494 U 20201119